Concord Biotech Limited
NSE: CONCORDBIO BSE: CONCORDBIO
Prev Close
1750.2
Open Price
1751
Volume
66,567
Today Low / High
1735 / 1763.8
52 WK Low / High
1345 / 2664
Range
1,651 - 1,825
Prev Close
1750.3
Open Price
1742
Volume
3,222
Today Low / High
1735 / 1760.7
52 WK Low / High
1370.05 / 2658
Range
1,653 - 1,827
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1737.7 (target range: 1,651 - 1,825), reflecting a change of -12.5 (-0.7142%). On the BSE, it is listed at 1739.6 (target range: 1,653 - 1,827), showing a change of -10.7 (-0.61132%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Concord Biotech Limited Graph
Concord Biotech Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Concord Biotech Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,737.70, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,739.60 | 1,757.00 | 1,581.30 - 1,932.70 |
| 1,774.39 | 1,419.51 - 2,129.27 | ||
| 1,791.79 | 1,254.25 - 2,329.32 | ||
| Bearish Scenario | 1,739.60 | 1,722.20 | 1,549.98 - 1,894.42 |
| 1,704.81 | 1,363.85 - 2,045.77 | ||
| 1,687.41 | 1,181.19 - 2,193.64 |
Overview of Concord Biotech Limited
ISIN
INE338H01029
Industry
Biotechnology
Vol.Avg
217,875
Market Cap
183,413,121,840
Last Dividend
8.75
Official Website
IPO Date
2023-08-18
DCF Diff
1,590.44
DCF
167
Financial Ratios Every Investor Needs
Stock Dividend of CONCORDBIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-06-21 | June 21, 24 | 8.75 | 8.75 | 2024-06-22 | 2024-07-29 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,200.09 Cr | 611.05 Cr | 589.04 Cr | 0.4908 | 0.00 Cr | 0.00 Cr | 451.96 Cr | 371.64 Cr | 35.52 | 550.78 Cr | 0.3097 |
| 2024-03-31 | 998.06 Cr | 244.78 Cr | 753.27 Cr | 0.7547 | 22.90 Cr | 11.13 Cr | 626.19 Cr | 308.10 Cr | 29.45 | 465.91 Cr | 0.3087 |
| 2023-03-31 | 853.17 Cr | 180.21 Cr | 672.96 Cr | 0.7888 | 32.83 Cr | 10.50 Cr | 326.52 Cr | 240.09 Cr | 22.95 | 383.22 Cr | 0.2814 |
| 2022-03-31 | 708.44 Cr | 177.92 Cr | 530.52 Cr | 0.7489 | 29.09 Cr | 10.58 Cr | 243.96 Cr | 174.93 Cr | 16.72 | 297.34 Cr | 0.2469 |
| 2021-03-31 | 604.05 Cr | 120.33 Cr | 483.73 Cr | 0.8008 | 0.00 Cr | 7.09 Cr | 306.89 Cr | 234.89 Cr | 22.45 | 341.74 Cr | 0.3889 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.18 Cr | 2,034.25 Cr | 221.53 Cr | 1,812.7175 Cr | 2.97 Cr | 1.79 Cr | 239.67 Cr | 844.22 Cr | 0.00 Cr | 0.00 Cr | 39.29 Cr | 184.0626 Cr |
| 2024-03-31 | 15.14 Cr | 1,700.71 Cr | 174.06 Cr | 1,526.6455 Cr | 9.74 Cr | -5.40 Cr | 207.95 Cr | 786.48 Cr | 3.66 Cr | 0.00 Cr | -263.36 Cr | 142.1554 Cr |
| 2023-03-31 | 3.50 Cr | 1,513.98 Cr | 223.98 Cr | 1,290.0010 Cr | 31.55 Cr | 28.05 Cr | 212.32 Cr | 765.48 Cr | 0.00 Cr | 0.00 Cr | -168.12 Cr | 191.8460 Cr |
| 2022-03-31 | 0.67 Cr | 1,312.80 Cr | 209.57 Cr | 1,103.2230 Cr | 62.49 Cr | 61.83 Cr | 195.12 Cr | 643.56 Cr | 0.00 Cr | 0.00 Cr | -160.85 Cr | 155.1680 Cr |
| 2021-03-31 | 5.14 Cr | 1,182.55 Cr | 183.17 Cr | 999.3730 Cr | 89.28 Cr | 84.14 Cr | 153.61 Cr | 557.75 Cr | 0.00 Cr | 0.00 Cr | -195.70 Cr | 105.7390 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 247.4104 Cr | -162.9811 Cr | -98.6669 Cr | 136.2382 Cr | 0.0000 Cr | 1.1831 Cr | -111.1722 Cr | 371.6423 Cr | -5.8487 Cr | -91.5392 Cr | -31.7134 Cr |
| 2024-03-31 | 265.4671 Cr | -154.6093 Cr | -99.2149 Cr | 179.7786 Cr | 11.6429 Cr | 15.1421 Cr | -85.6885 Cr | 308.1032 Cr | -26.5036 Cr | -71.4529 Cr | 4.3609 Cr |
| 2023-03-31 | 246.0018 Cr | -157.9501 Cr | -85.2194 Cr | 100.9170 Cr | 2.8323 Cr | 3.4992 Cr | -145.0848 Cr | 322.0134 Cr | -26.5961 Cr | -53.5635 Cr | -17.2273 Cr |
| 2022-03-31 | 207.4750 Cr | -111.7880 Cr | -100.1640 Cr | 51.9700 Cr | -4.4770 Cr | 0.6670 Cr | -155.5050 Cr | 237.5180 Cr | -26.6557 Cr | -70.5210 Cr | -41.5090 Cr |
| 2021-03-31 | 166.8170 Cr | -195.2050 Cr | 31.1240 Cr | -37.3590 Cr | 2.7360 Cr | 5.1440 Cr | -204.1760 Cr | 312.7200 Cr | 38.3210 Cr | -5.7060 Cr | -42.3770 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 429.88 Cr | 211.42 Cr | 218.47 Cr | 0.5082 | 175.81 Cr | 140.39 Cr | 13.42 | 199.81 Cr | 0.3266 |
| 2024-12-31 | 244.22 Cr | 52.40 Cr | 191.82 Cr | 0.7854 | 84.69 Cr | 75.92 Cr | 7.26 | 114.51 Cr | 0.3109 |
| 2024-09-30 | 310.18 Cr | 76.32 Cr | 233.86 Cr | 0.7540 | 123.36 Cr | 95.74 Cr | 9.15 | 143.75 Cr | 0.3087 |
| 2024-06-30 | 215.80 Cr | 48.30 Cr | 167.50 Cr | 0.7762 | 135.84 Cr | 59.59 Cr | 5.70 | 91.59 Cr | 0.2761 |
| 2024-03-31 | 318.97 Cr | 88.84 Cr | 230.13 Cr | 0.7215 | 129.18 Cr | 95.02 Cr | 9.08 | 145.10 Cr | 0.2979 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.18 Cr | 316.54 Cr | 317.73 Cr | 521.65 Cr | 239.67 Cr | 1,135.24 Cr | 844.22 Cr | 2,034.25 Cr | 221.53 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 283.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,590.38 Cr |
| 2024-09-30 | 7.40 Cr | 310.89 Cr | 318.29 Cr | 0.00 Cr | 250.42 Cr | 934.65 Cr | 806.03 Cr | 1,764.34 Cr | 173.97 Cr |
| 2024-06-30 | -281.67 Cr | 563.33 Cr | 281.67 Cr | 0.00 Cr | 0.00 Cr | 281.67 Cr | 0.00 Cr | 0.00 Cr | -1,526.65 Cr |
| 2024-03-31 | 15.14 Cr | 295.03 Cr | 310.18 Cr | 369.04 Cr | 207.95 Cr | 896.23 Cr | 786.48 Cr | 1,700.71 Cr | 174.06 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 75.92 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 95.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 59.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 95.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 77.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹380.05 | ₹507,147,490,794.00 | ₹6,783,821.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹203.66 | ₹270,714,688,412.00 | ₹5,933,274.00 |
| Syngene International Limited | SYNGENE | ₹644.20 | ₹258,772,114,193.00 | ₹165,596.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,737.70 | ₹181,791,570,740.00 | ₹66,567.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹897.25 | ₹155,641,848,095.00 | ₹436,850.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹788.30 | ₹125,561,212,300.00 | ₹496,771.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹735.30 | ₹59,179,002,840.00 | ₹491,772.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹262.40 | ₹41,139,859,200.00 | ₹134,219.00 |
| Zota Health Care Limited | ZOTA | ₹1,199.80 | ₹33,453,423,500.00 | ₹394,813.00 |
Key Executives
Gender: male
Year Born:
Gender: Not Specified
Year Born:
Gender: male
Year Born: 1952
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1982
FAQs about Concord Biotech Limited
The CEO is Ankur Vaid.
The current price is ₹1,753.20.
The range is ₹1345-2664.
The market capitalization is ₹18,341.31 crores.
The P/E ratio is 49.34.
The company operates in the Healthcare sector.
Overview of Concord Biotech Limited (ISIN: INE338H01029) is a leading Biotechnology in India. With a market capitalization of ₹18,341.31 crores and an average daily volume of 217,875 shares, it operates in the Biotechnology. The company last declared a dividend of ₹8.75.